(Q34463979)

2 August 2017

1 reference

title

Carboplatin versus cisplatin in solid tumors: an analysis of the literature (English)

1 reference

2 August 2017

1 reference

1 reference

J Lokich

1

1 reference

PubMed ID

9541678

2 August 2017

N Anderson

series ordinal

2

1 reference

2 August 2017

1 January 1998

1 reference

2 August 2017

1 reference

2 August 2017

9

1 reference

2 August 2017

13-21

1 reference

2 August 2017

1

1 reference

A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia

2 August 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Clinical Pharmacokinetics of Carboplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Combination cisplatin and carboplatin in advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Carboplatin in combination therapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Crossover study with cisplatin or carboplatin in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Carboplatin and cisplatin: are they equivalent in efficacy in "optimal residual" advanced ovarian cancer?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Carboplatin in the combination chemotherapy of non-seminomatous germ cell tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Resear

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Dose-intensity in ovarian carcinoma: hold, enough?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008215213739

7 January 2021

Identifiers

DOI

10.1023/A:1008215213739

1 reference

2 August 2017

1 reference

PubMed ID

9541678